Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
5.25
-0.06 (-1.13%)
At close: Dec 4, 2024, 4:00 PM
5.39
+0.14 (2.67%)
After-hours: Dec 4, 2024, 5:30 PM EST

Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.

It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.

Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.
Sagimet Biosciences logo
Country United States
Founded 2006
IPO Date Jul 14, 2023
Industry Biotechnology
Sector Healthcare
Employees 10
CEO David Happel

Contact Details

Address:
155 Bovet Road, Suite 303
San Mateo, California 94402
United States
Phone 650 561 8600
Website sagimet.com

Stock Details

Ticker Symbol SGMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001400118
CUSIP Number 786700104
ISIN Number US7867001049
Employer ID 20-5991472
SIC Code 2834

Key Executives

Name Position
David A. Happel Chief Executive Officer, President and Director
Dr. George W. Kemble Ph.D. Executive Chairman of the Board
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. Chief Medical Officer
Urs Greber Ph.D. Co-Founder
Dr. Lucas Pelkmans Ph.D. Co-Founder
Thierry Chauche Chief Financial Officer and Principal Accounting Officer
Elizabeth Rozek Esq., J.D. General Counsel and Chief Compliance Officer
Dr. Marie O'Farrell Ph.D. Senior Vice President of Research and Development
Robert D'Urso Senior Vice President of New Products

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Aug 26, 2024 EFFECT Notice of Effectiveness
Aug 19, 2024 UPLOAD Filing
Aug 16, 2024 8-K Current Report
Aug 15, 2024 S-3 Registration statement under Securities Act of 1933